SourceThe Next Web (TNW)•Stalecollected in 70m
Tissium raises €60M for FDA-cleared sutureless nerve glue
A breakthrough in surgical tech: FDA-cleared light-cured glue replacing sutures for nerve repair.
30-Second TL;DR
What Changed
Tissium raised €60M in funding.
Why It Matters
This innovation could significantly reduce surgical time and improve recovery outcomes for nerve-related procedures. It represents a shift toward bio-adhesive technologies in precision surgery.
What To Do Next
If you are in the medical AI or robotics field, monitor how bio-adhesives integrate with robotic surgery platforms.
Who should care:Researchers & Academics
Key Points
- •Tissium raised €60M in funding.
- •The product is the world's only FDA-cleared sutureless nerve repair system.
- •It uses light-cured glue to replace traditional surgical needles.
- •The company is expanding its operations into US operating rooms.
Deep Insight
AI-generated analysis for this event — not the original article.
Enhanced Key Takeaways
- •Tissium's technology platform is based on proprietary polymers developed at the University of Paris, specifically leveraging light-activated adhesive chemistry.
- •The company's nerve repair system, marketed as TISSIUM Nerve, received FDA De Novo classification, marking a significant regulatory milestone for synthetic nerve adhesives.
- •Beyond nerve repair, Tissium is developing a broader pipeline of products including sealants for cardiovascular, gastrointestinal, and hernia repair applications.
- •The €60M funding round was led by a mix of existing investors and new strategic partners, aimed at scaling manufacturing and establishing a US commercial infrastructure.
- •The adhesive mechanism relies on a biocompatible, biodegradable polymer that crosslinks upon exposure to specific wavelengths of light, allowing for precise control over the setting time during surgery.
Competitor Analysis
Traditional Sutures
- Technology Type
- Mechanical
- Key Limitation
- High risk of nerve trauma/inflammation
- FDA Status
- Cleared
Fibrin Glues
- Technology Type
- Biological
- Key Limitation
- Lower mechanical strength
- FDA Status
- Cleared
Cyanoacrylates
- Technology Type
- Synthetic
- Key Limitation
- High toxicity/exothermic reaction
- FDA Status
- Limited/Off-label
| Competitor | Technology Type | Key Limitation | FDA Status |
|---|---|---|---|
| Traditional Sutures | Mechanical | High risk of nerve trauma/inflammation | Cleared |
| Fibrin Glues | Biological | Lower mechanical strength | Cleared |
| Cyanoacrylates | Synthetic | High toxicity/exothermic reaction | Limited/Off-label |
Technical Deep Dive
- Platform Chemistry: Utilizes a light-activated, biodegradable polymer network that forms a covalent bond with tissue surfaces.
- Application Method: Delivered via a specialized applicator that integrates a light source to trigger polymerization in situ.
- Mechanical Properties: Designed to provide immediate tensile strength while maintaining flexibility to accommodate nerve movement.
- Degradation Profile: The polymer is engineered to degrade via hydrolysis at a rate synchronized with the natural nerve healing process.
- Biocompatibility: Formulated to minimize the inflammatory response typically associated with foreign body reactions in nerve tissue.
Future ImplicationsAI analysis grounded in cited sources
Tissium will disrupt the market for microsurgical nerve repair tools.
By eliminating the need for needles and sutures, the system reduces surgical time and the risk of secondary nerve damage caused by mechanical piercing.
The company will pivot toward broader soft-tissue sealing applications.
The versatility of their light-cured polymer platform allows for easy adaptation into cardiovascular and gastrointestinal surgical markets.
Timeline
2013-01
Tissium is founded as a spin-off from the University of Paris.
2019-09
Company secures €50M in Series B funding to advance its polymer platform.
2024-05
Tissium receives FDA De Novo authorization for its nerve repair system.
2026-06
Tissium raises €60M to support US commercial expansion.
- 2013-01Tissium is founded as a spin-off from the University of Paris.
- 2019-09Company secures €50M in Series B funding to advance its polymer platform.
- 2024-05Tissium receives FDA De Novo authorization for its nerve repair system.
- 2026-06Tissium raises €60M to support US commercial expansion.
Weekly AI Recap
Read this week's curated digest of top AI events →
Related Updates
AI-curated news aggregator. All content rights belong to original publishers.
Original source: The Next Web (TNW) ↗
This is a summary, not the original. Read the source, or get the weekly briefing.
The weekly digest
One email a week. Unsubscribe anytime.